This article is more than 5 years old. Information may no longer be current.

Ocugen's dry eye combination product shows positive phase 2 results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A phase 2 proof-of-concept clinical trial of OCU310, a combination of brimonidine tartrate and loteprednol etabonate, has shown meaningful improvements in patients with dry eye disease, according to an Ocugen press release.

Over a 12-week period, the randomized, multicenter, double-masked, placebo-controlled study met its primary endpoint of tolerability, the release said. In addition, it showed meaningful improvements related to dry eye signs and symptoms compared with placebo.

“We believe OCU310 can provide significant benefit to those suffering from dry eye disease, and we look forward to presenting the full results at a future academic meeting and discussing with the FDA in the coming months,” Daniel Jorgensen, MD, MPH, Ocugen chief medical officer, said in the release.

Phase 3 clinical studies of OCU310 are expected to begin in the third quarter of this year.